JP2022188234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022188234A5 JP2022188234A5 JP2022162309A JP2022162309A JP2022188234A5 JP 2022188234 A5 JP2022188234 A5 JP 2022188234A5 JP 2022162309 A JP2022162309 A JP 2022162309A JP 2022162309 A JP2022162309 A JP 2022162309A JP 2022188234 A5 JP2022188234 A5 JP 2022188234A5
- Authority
- JP
- Japan
- Prior art keywords
- irna agent
- nucleotides
- pharmaceutical composition
- uridine
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 25
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 7
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims 3
- 101710194189 Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014418 Electrolyte imbalance Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000026709 Liddle syndrome Diseases 0.000 claims 1
- 208000037273 Pathologic Processes Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- -1 dimethylaminoethyloxyethyl Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000009054 pathological process Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07110376.6 | 2007-06-15 | ||
| EP07110376 | 2007-06-15 | ||
| EP07114265.7 | 2007-08-13 | ||
| EP07114265 | 2007-08-13 | ||
| JP2020046007A JP7157775B2 (ja) | 2007-06-15 | 2020-03-17 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046007A Division JP7157775B2 (ja) | 2007-06-15 | 2020-03-17 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022188234A JP2022188234A (ja) | 2022-12-20 |
| JP2022188234A5 true JP2022188234A5 (enExample) | 2023-07-18 |
Family
ID=40130244
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511658A Expired - Fee Related JP5485146B2 (ja) | 2007-06-15 | 2008-06-13 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2014029519A Expired - Fee Related JP5719047B2 (ja) | 2007-06-15 | 2014-02-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2015055783A Expired - Fee Related JP6193906B2 (ja) | 2007-06-15 | 2015-03-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2017149211A Expired - Fee Related JP6680728B2 (ja) | 2007-06-15 | 2017-08-01 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2020046007A Active JP7157775B2 (ja) | 2007-06-15 | 2020-03-17 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2022162309A Pending JP2022188234A (ja) | 2007-06-15 | 2022-10-07 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511658A Expired - Fee Related JP5485146B2 (ja) | 2007-06-15 | 2008-06-13 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2014029519A Expired - Fee Related JP5719047B2 (ja) | 2007-06-15 | 2014-02-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2015055783A Expired - Fee Related JP6193906B2 (ja) | 2007-06-15 | 2015-03-19 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2017149211A Expired - Fee Related JP6680728B2 (ja) | 2007-06-15 | 2017-08-01 | α−ＥＮａＣ発現のＲＮＡｉ阻害 |
| JP2020046007A Active JP7157775B2 (ja) | 2007-06-15 | 2020-03-17 | α－ＥＮａＣ発現のＲＮＡｉ阻害 |
Country Status (26)
| Country | Link |
|---|---|
| US (12) | US7718632B2 (enExample) |
| EP (7) | EP2223694B1 (enExample) |
| JP (6) | JP5485146B2 (enExample) |
| KR (2) | KR101653008B1 (enExample) |
| CN (1) | CN101778941B (enExample) |
| AR (1) | AR066984A1 (enExample) |
| AU (1) | AU2008263876B2 (enExample) |
| BR (1) | BRPI0813680A8 (enExample) |
| CA (1) | CA2690674C (enExample) |
| CL (1) | CL2008001756A1 (enExample) |
| CO (1) | CO6251331A2 (enExample) |
| CR (1) | CR11136A (enExample) |
| CU (1) | CU23774A3 (enExample) |
| EA (1) | EA200901653A1 (enExample) |
| EC (1) | ECSP099794A (enExample) |
| ES (6) | ES2432643T3 (enExample) |
| GT (1) | GT200900315A (enExample) |
| IL (1) | IL202366A0 (enExample) |
| MA (1) | MA31564B1 (enExample) |
| MX (1) | MX2009013609A (enExample) |
| PE (1) | PE20090942A1 (enExample) |
| SG (3) | SG10201404955RA (enExample) |
| SV (1) | SV2009003434A (enExample) |
| TN (1) | TN2009000521A1 (enExample) |
| TW (3) | TWI444474B (enExample) |
| WO (1) | WO2008152131A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2884658A1 (en) | 2002-07-26 | 2004-02-05 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| KR100473148B1 (ko) * | 2002-11-27 | 2005-03-10 | (주)텔리언 | 버스트모드 패킷 전달을 위한 정합장치 및 방법 |
| EP1796732B1 (en) * | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EA201100847A1 (ru) * | 2008-11-26 | 2012-01-30 | Мерк Шарп Энд Домэ Корп. | Опосредованное рнк-интерференцией ингибирование экспрессии генов эпителиального натриевого канала (enac) c использованием малой интерферирующей нуклеиновой кислоты (минк) |
| WO2010111891A1 (zh) * | 2009-04-03 | 2010-10-07 | 北京大学 | 修饰的寡聚核酸分子及其制备方法和应用 |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| CN103275978B (zh) * | 2009-04-03 | 2014-10-29 | 百奥迈科生物技术有限公司 | 修饰的小干扰核酸及其制备方法 |
| US20120207818A1 (en) * | 2009-07-14 | 2012-08-16 | Shinohara Fumikazu | Composition for suppressing expression of target gene |
| EP3252068B1 (en) * | 2009-10-12 | 2025-07-02 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| KR101605932B1 (ko) | 2009-12-18 | 2016-03-24 | 노파르티스 아게 | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 |
| JP5857378B2 (ja) * | 2010-04-23 | 2016-02-10 | アローヘッド リサーチ コーポレイション | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| EP2694670B1 (en) | 2011-04-08 | 2017-07-19 | Bio-Rad Laboratories, Inc. | Pcr reaction mixtures with decreased non-specific activity |
| EP2699271A4 (en) | 2011-04-20 | 2015-10-07 | Larry J Smith | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY |
| MX344807B (es) * | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| EP3098314B1 (en) | 2011-09-02 | 2019-03-13 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| IL305158A (en) | 2016-11-01 | 2023-10-01 | Arrowhead Pharmaceuticals Inc | Ligands of alpha-V beta-6 integrin and their uses |
| CR20190572A (es) * | 2017-07-06 | 2020-05-23 | Arrowhead Pharmaceuticals Inc | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO |
| CN111372594A (zh) * | 2017-10-31 | 2020-07-03 | Ionis制药公司 | ENaC表达的调节剂 |
| JP7445594B2 (ja) * | 2017-11-01 | 2024-03-07 | アローヘッド ファーマシューティカルズ インコーポレイテッド | インテグリンリガンドおよびその使用 |
| CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
| WO2021041776A1 (en) * | 2019-08-30 | 2021-03-04 | United States Government As Represented By The Department Of Veterans Affairs | Liposomal troponoid compound formulations |
| US12415840B2 (en) | 2020-02-21 | 2025-09-16 | Brookhaven Science Associates, Llc | Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation |
| AU2022254705A1 (en) | 2021-04-08 | 2023-10-05 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| US11957178B2 (en) | 2021-11-15 | 2024-04-16 | Apackaging Group Llc | Aerosol actuator |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4837026A (en) * | 1985-10-03 | 1989-06-06 | Rajakhyaksha Vithal J | Transdermal and systemic preparation and method |
| DE3604625C2 (de) * | 1986-02-14 | 1994-01-20 | Bmw Rolls Royce Gmbh | Gasturbine |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US5451670A (en) * | 1987-12-09 | 1995-09-19 | City Of Hope | Restriction fragment length polymorphism test for haplotyping domesticated fowl |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| US5013566A (en) * | 1988-12-19 | 1991-05-07 | Sampson Michael James | Process for obtaining improved yields from plants used for hay making by using a coating agent |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| KR100334858B1 (ko) | 1993-02-19 | 2006-01-27 | 니뽄 신야쿠 가부시키가이샤 | 핵산공중합체를함유하는의약조성물 |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| JP3543347B2 (ja) * | 1994-01-24 | 2004-07-14 | 日本油脂株式会社 | 点火薬造粒物の製造方法 |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| DE69629702T2 (de) | 1995-08-01 | 2004-06-17 | Isis Pharmaceuticals, Inc., Carlsbad | Liposomale oligonukleotidzusammensetzungen |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| US5865710A (en) * | 1996-08-01 | 1999-02-02 | Wilson-Hyde; Cynthia | Step aerobic platform |
| US6551775B1 (en) * | 1997-03-11 | 2003-04-22 | Yale University | Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1 |
| ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US5976849A (en) | 1998-02-05 | 1999-11-02 | Zeneca Limited | Human E3 ubiquitin protein ligase |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20030064385A1 (en) | 2001-05-16 | 2003-04-03 | Dressman Marlene Michelle | Genes expressed in breast cancer as prognostic and therapeutic targets |
| AU2002364612A1 (en) | 2001-12-31 | 2003-07-24 | Algos Therapeutics, Inc. | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
| CA2884658A1 (en) * | 2002-07-26 | 2004-02-05 | Novartis Vaccines And Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| MXPA05005653A (es) | 2002-11-27 | 2005-11-23 | Artesian Therapeutics Inc | Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca. |
| WO2004050694A1 (en) | 2002-11-29 | 2004-06-17 | Basf Aktiengesellschaft | Methods for the production of methionine |
| DE10305213A1 (de) | 2003-02-07 | 2004-08-26 | Florian Prof. Dr.med. Lang | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
| AU2004227915A1 (en) * | 2003-03-31 | 2004-10-21 | John F. Engelhardt | Pharmico-gene theraphy of epithelial sodium channel associated disoders |
| US7723509B2 (en) * | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
| JP4530335B2 (ja) * | 2004-02-03 | 2010-08-25 | 独立行政法人科学技術振興機構 | 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬 |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| SE0402832D0 (sv) * | 2004-11-18 | 2004-11-18 | Astrazeneca Ab | Methods |
| US7923206B2 (en) * | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
| US7361752B2 (en) * | 2004-12-14 | 2008-04-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| US20070149456A1 (en) * | 2005-12-13 | 2007-06-28 | University Of Pittsburgh | Epithelial sodium channel inhibiting agents and uses therefor |
| BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| WO2008043561A2 (en) | 2006-10-11 | 2008-04-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza targets |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
-
2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/es not_active Application Discontinuation
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/en active Active
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/en active Active
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/pt not_active IP Right Cessation
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/es active IP Right Grant
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/en active Active
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/en not_active Ceased
- 2008-06-13 ES ES10163496T patent/ES2432643T3/es active Active
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/es not_active Application Discontinuation
- 2008-06-13 TW TW097122240A patent/TWI444474B/zh not_active IP Right Cessation
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/en active Active
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/es active Active
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/es unknown
- 2008-06-13 ES ES10163499T patent/ES2432157T3/es active Active
- 2008-06-13 TW TW105120348A patent/TWI629063B/zh not_active IP Right Cessation
- 2008-06-13 EA EA200901653A patent/EA200901653A1/ru unknown
- 2008-06-13 CA CA2690674A patent/CA2690674C/en active Active
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/ko active Active
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/ja not_active Expired - Fee Related
- 2008-06-13 ES ES10163501T patent/ES2432158T3/es active Active
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/ko not_active Expired - Fee Related
- 2008-06-13 EP EP08761002A patent/EP2171059A2/en not_active Withdrawn
- 2008-06-13 ES ES10163500T patent/ES2432644T3/es active Active
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/en active Active
- 2008-06-13 ES ES10163502T patent/ES2432532T3/es active Active
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/en active Active
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/zh active Active
- 2008-06-13 TW TW103118914A patent/TWI552753B/zh not_active IP Right Cessation
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
-
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/es not_active Application Discontinuation
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/fr unknown
- 2009-12-11 CO CO09142201A patent/CO6251331A2/es not_active Application Discontinuation
- 2009-12-11 GT GT200900315A patent/GT200900315A/es unknown
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/es unknown
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/es unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/es not_active IP Right Cessation
-
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/fr unknown
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
- 2010-04-30 US US12/771,614 patent/US8168606B2/en not_active Expired - Fee Related
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
-
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/ja not_active Expired - Fee Related
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
-
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
-
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
-
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en active Active
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/ja active Active
-
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
-
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022188234A5 (enExample) | ||
| JP2020094063A5 (enExample) | ||
| AU2006279906B2 (en) | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof | |
| US7998940B2 (en) | Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics | |
| US7589073B2 (en) | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics | |
| JP2008523157A5 (enExample) | ||
| US7566701B2 (en) | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics | |
| JP2003520811A5 (enExample) | ||
| AU2017326372B2 (en) | Modified oligonucleotides and methods of use | |
| JP2005500025A5 (enExample) | ||
| JP2008283975A5 (enExample) | ||
| JP2005524393A5 (enExample) | ||
| WO2006034348A2 (en) | Enhanced antisense oligonucleotides | |
| JP2005517452A5 (enExample) | ||
| EP2844757A2 (en) | Organic compositions to treat kras-related diseases | |
| WO2009091972A2 (en) | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof | |
| TW202137987A (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| HK1214301A1 (zh) | 治療epas1相關疾病的有機組合物 | |
| JP2009502138A5 (enExample) | ||
| RU2008121953A (ru) | Ирнк-ингибирование репликации вируса гриппа | |
| CN120712356A (zh) | 一种抑制f11基因表达的核酸分子 | |
| JP7725370B2 (ja) | Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 | |
| EP4347828A1 (en) | Short duplex dna as a novel gene silencing technology and use thereof | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| RU2822093C1 (ru) | Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке |